57th ASH Annual Meeting and Exposition (December 5-8, 2015): 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targeting Approaches

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation Oral and Poster Abstracts
Oral

W109, Level 1 (Orange County Convention Center)

Moderators:

Ronan T. Swords, MD, PhD, FRCPI, FRCPath, Sylvester Comprehensive Cancer Center, University of Miami Hospitals and Raoul Tibes, MD, PhD, Mayo Clinic Scottsdale Arizona

Disclosures:

No relevant conflicts of interest to declare.

10:30 AM

565

Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity

Sarah K Tasian, MD^1,2,3, Saad S Kenderian, MD^4,5, Feng Shen, MD PhD⁶^*, Yong Li, MD MS⁶^*, Marco Ruella, MD⁷^*, William C Fix, BA⁶^*, Miroslaw Kozlowski, PhD⁷^*, Martin Carroll, MD^3,8, Richard Aplenc, MD, PhD^1,9,10, Carl H June, MD^3,7,11, Stephan A Grupp, MD, PhD^1,2,3 and Saar I Gill, MBBS, PhD^3,4,12

¹Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
²Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA
³Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA
⁴Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
⁵Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN
⁶Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
⁷Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA
⁸Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
⁹Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
¹⁰Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA
¹¹Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA
¹²Department of Medicine, Division of Hematology and Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA

10:45 AM

566

A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells

Jeffrey S. Miller, MD¹, Michael R. Verneris, MD¹, Julie Curtsinger, Ph.D.¹^*, Todd E. DeFor, MS¹^*, David McKenna, MD¹, Thomas A Waldmann, MD², Bruce R. Blazar, MD¹, Daniel J. Weisdorf, MD¹ and Sarah Cooley, MD¹

¹Adult and Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN
²Lymphoid Malignancies Branch, National Cancer Institute, National Cancer Institute NIH, Bethesda, MD

11:00 AM

567

RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance

Leslie A Crews, PhD^1,2^*, Larissa Balaian, Ph.D.³, Heather Leu, BS²^*, Nathaniel Delos Santos²^*, Angela C Court²^*, Anil Sadarangani, PhD⁴^*, Maria A. Zipeto, PhD²^*, James J La Clair⁵^*, Reymundo Villa⁵^*, Sheldon Morris, MD⁶^*, Rainer F. Storb, MD⁷, Anna Kulidjian, MD⁸^*, Edward D. Ball, MD⁹, Michael D Burkart, PhD⁵^* and Catriona Jamieson, MD, PhD^1,2,3

¹Sanford Consortium for Regenerative Medicine, La Jolla, CA
²Division of Regenerative Medicine, University of California, San Diego, La Jolla, CA
³Moores Cancer Center, University of California, San Diego, La Jolla, CA
⁴Division of Regenerative Medicine, University of California San Diego, La Jolla, CA
⁵Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA
⁶Department of Medicine, University of California, San Diego, La Jolla, CA
⁷Fred Hutchinson Cancer Research Center, Seattle, WA
⁸Department of Orthopedic Surgery, University of California San Diego, La Jolla, CA
⁹Division of Bone Marrow Transplantation, Department of Medicine, University of California, San Diego, La Jolla, CA

11:15 AM

568

Blu-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations

Erica Evans, PhD^*, Alexandra Gardino, PhD^*, Brian Hodous, PhD^*, Alison Davis, PhD^*, Julia Zhu, M.S.^*, Nancy E. Kohl, PhD^* and Christoph Lengauer, PhD^*

Blueprint Medicines, Cambridge, MA

11:30 AM

569

A Novel STAT3 Inhibitor Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia That Incorporate the Stromal Environment

Michael J Krueger, BS¹^*, Matthew Minus, BS²^*, Wei Liu, PhD³^*, Xin Long, PhD¹^*, Alexandra M. Stevens, MD¹, Mikhail I. Kolosov, BS⁴^*, Edward Allan R. Sison, MD¹, David John Tweardy, MD⁴, Zachary T. Ball, PhD²^* and Michele S. Redell, MD, PhD¹

¹Pediatrics, Hematology/Oncology, Baylor College of Medicine, Houston, TX
²Chemistry, Rice University, Houston, TX
³Arcadia University, Glenside, PA
⁴MD Anderson Cancer Center, Houston, TX

11:45 AM

570

Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia

Megan M Cleary, B.S., B.A.¹^*, Rhese Thompson¹^*, Shawn Mahmood, B.S., B.A.¹^*, Monika Davare, PhD²^*, Steve Kurtz, PhD¹^*, Johannes Elferich, PhD³^*, Ujwal Shinde, PhD³^*, Brian J. Druker, MD^1,4, Jack Singer, MD⁵ and Anupriya Agarwal, PhD¹

¹Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
²Department of Pediatrics, Oregon Health and Science University, Portland, OR
³Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, OR
⁴Howard Hughes Medical Institute, Portland, OR
⁵CTI BioPharma, Corp, Seattle, WA

See more of: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

616.O3.6 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targeting Approaches